SCHEMBL3017217

SCHEMBL3017217

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.44
LPAR2 Q9HBW0 1/20 0.44
LMNA P02545 3/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TRPV4 Q9HBA0 1/20 0.43
HTT P42858 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD11B1 P28845 1/20 0.40
THRB P10828 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
POLB P06746 3/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ATM Q13315 1/20 0.37
TSHR P16473 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015032 0.93 MAPT (0.46) LMNAMAPTNPSR1HTTKDM4E
SCHEMBL3023443 0.91 ALDH1A1 (0.42) LPAR1LPAR2LMNAMAPTNPSR1
SCHEMBL3003958 0.91 LPAR1 (0.37) LPAR1LPAR2LMNAMAPTNPSR1
SCHEMBL3013342 0.90 TRPV4 (0.45) LPAR1LPAR2NPSR1TRPV4HTT
SCHEMBL3021382 0.90 TRPV4 (0.48) LPAR1LPAR2LMNAMAPTTRPV4
SCHEMBL3016519 0.90 MAPT (0.43) LMNAMAPTNPSR1ALDH1A1CNR1
SCHEMBL3002366 0.90 LMNA (0.39) LMNAMAPTNPSR1HTTKDM4E
SCHEMBL3008939 0.89 TRPV4 (0.46) LPAR1LPAR2LMNAMAPTTRPV4
SCHEMBL3655521 0.89 ALDH1A1 (0.39) LPAR1LPAR2LMNAMAPTNPSR1
SCHEMBL3018571 0.89 TRPV4 (0.45) LPAR1LPAR2LMNAMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LPAR1 2066/4885LPAR2 1732/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.